SIONNA THERAPEUTICS INC (SION) Fundamental Analysis & Valuation

NASDAQ:SION • US8294011080

Current stock price

39.15 USD
+0.45 (+1.16%)
At close:
39.15 USD
0 (0%)
After Hours:

This SION fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SION Profitability Analysis

1.1 Basic Checks

  • In the past year SION has reported negative net income.
  • In the past year SION has reported a negative cash flow from operations.
SION Yearly Net Income VS EBIT VS OCF VS FCFSION Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • SION has a better Return On Assets (-23.09%) than 72.43% of its industry peers.
  • With a decent Return On Equity value of -24.53%, SION is doing good in the industry, outperforming 78.83% of the companies in the same industry.
Industry RankSector Rank
ROA -23.09%
ROE -24.53%
ROIC N/A
ROA(3y)-49.1%
ROA(5y)N/A
ROE(3y)-66.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SION Yearly ROA, ROE, ROICSION Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • SION does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SION Yearly Profit, Operating, Gross MarginsSION Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. SION Health Analysis

2.1 Basic Checks

  • SION has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for SION. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SION Yearly Shares OutstandingSION Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
SION Yearly Total Debt VS Total AssetsSION Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 53.49 indicates that SION is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of SION (53.49) is better than 95.53% of its industry peers.
  • SION has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 53.49
ROIC/WACCN/A
WACCN/A
SION Yearly LT Debt VS Equity VS FCFSION Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • SION has a Current Ratio of 20.61. This indicates that SION is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 20.61, SION belongs to the top of the industry, outperforming 94.56% of the companies in the same industry.
  • A Quick Ratio of 20.61 indicates that SION has no problem at all paying its short term obligations.
  • The Quick ratio of SION (20.61) is better than 94.56% of its industry peers.
Industry RankSector Rank
Current Ratio 20.61
Quick Ratio 20.61
SION Yearly Current Assets VS Current LiabilitesSION Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SION Growth Analysis

3.1 Past

  • The earnings per share for SION have decreased strongly by -29.82% in the last year.
EPS 1Y (TTM)-29.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SION is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.76% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.82%
EPS Next 2Y-16.55%
EPS Next 3Y-15.21%
EPS Next 5Y-6.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SION Yearly Revenue VS EstimatesSION Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
SION Yearly EPS VS EstimatesSION Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SION Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SION. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SION. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SION Price Earnings VS Forward Price EarningsSION Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SION Per share dataSION EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as SION's earnings are expected to decrease with -15.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.55%
EPS Next 3Y-15.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SION Dividend Analysis

5.1 Amount

  • SION does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SION Fundamentals: All Metrics, Ratios and Statistics

SIONNA THERAPEUTICS INC

NASDAQ:SION (5/1/2026, 5:50:47 PM)

After market: 39.15 0 (0%)

39.15

+0.45 (+1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-02
Earnings (Next)05-18
Inst Owners73.33%
Inst Owner Change-0.02%
Ins Owners1.37%
Ins Owner Change0%
Market Cap1.76B
Revenue(TTM)N/A
Net Income(TTM)-75.27M
Analysts83.75
Price Target50.09 (27.94%)
Short Float %12.38%
Short Ratio10.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.57%
Min EPS beat(2)6.88%
Max EPS beat(2)16.27%
EPS beat(4)3
Avg EPS beat(4)3.72%
Min EPS beat(4)-35.83%
Max EPS beat(4)27.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.48%
PT rev (3m)9.48%
EPS NQ rev (1m)-0.65%
EPS NQ rev (3m)4.78%
EPS NY rev (1m)-3.63%
EPS NY rev (3m)-3.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.74
P/tB 5.74
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-2.38
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS6.82
TBVpS6.82
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -23.09%
ROE -24.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.1%
ROA(5y)N/A
ROE(3y)-66.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.61
Quick Ratio 20.61
Altman-Z 53.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)84.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.39%
EPS Next Y-21.82%
EPS Next 2Y-16.55%
EPS Next 3Y-15.21%
EPS Next 5Y-6.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.04%
EBIT Next 3Y-21.61%
EBIT Next 5Y-2.48%
FCF growth 1Y-26.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.59%
OCF growth 3YN/A
OCF growth 5YN/A

SIONNA THERAPEUTICS INC / SION Fundamental Analysis FAQ

What is the fundamental rating for SION stock?

ChartMill assigns a fundamental rating of 3 / 10 to SION.


What is the valuation status for SION stock?

ChartMill assigns a valuation rating of 0 / 10 to SIONNA THERAPEUTICS INC (SION). This can be considered as Overvalued.


What is the profitability of SION stock?

SIONNA THERAPEUTICS INC (SION) has a profitability rating of 1 / 10.


What is the financial health of SIONNA THERAPEUTICS INC (SION) stock?

The financial health rating of SIONNA THERAPEUTICS INC (SION) is 8 / 10.